ArticleFrontiers in genetics2025
Study on the mechanism of KIF18B affecting the malignant progression of glioblastoma cells.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network.International journal of molecular sciences · 2026Article
- Editorial: Screening and discovering novel biological biomarkers by omic-data to revolutionize tumor management.Frontiers in genetics · 2025Article
- A systems biology approach to unveil shared therapeutic targets and pathological pathways across major human cancers.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Member of the driver protein family 18B (KIF18B) is a potential prognostic marker and is highly expressed in a variety of cancers. However, its function in glioblastoma (GBM) remains unclear. Methods: The expression data of KIF18B were obtained by accessing TCGA, CGGA and GEPIA databases, and verified by Western blot assay and immunohistochemistry. Glioma RNA sequencing data and clinical information were downloaded from TCGA and CGGA databases, and Kaplan-plotter survival analysis and Multivariable COX regression analysis were performed to plot ROC survival curves at 1, 3 and 5 years cBioPortal and MethSurv were used to carefully examine the prognostic value of KIF18B methylation. CBioPortal database and UALCAN database were used to obtain KIF18B co-expressed genes for GO and KEGG enrichment analysis, and gene set enrichment analysis (GSEA) software was used to explore the signaling pathway of KIF18B regulation of GBM. Finally, the correlation between KIF18B and GBM infiltration was studied by using TIMER database and TCGA dataset. Results: KIF18B was highly expressed in various cancers including GBM, and was positively correlated with glioma grade and negatively correlated with prognosis. Multivariable COX regression analysis and ROC curve showed that KIF18B was one of the independent risk factors for glioma prognosis. KIF18B methylation was negatively correlated with KIF18B expression, and the overall survival rate of patients with KIF18B hypomethylation was lower than that of patients with KIF18B hypermethylation. A total of 124 co-expressed genes were selected from the database. KEGG pathway analysis showed that KIF18B was mainly involved in the malignant progression of glioma through P53 and other signaling pathways. GSEA analysis showed that the high expression group of KIF18B was mainly enriched in E2F, G2M and other signaling pathways. The results of immunoassay showed that the expression of KIF18B was correlated with immune infiltration of tumor microenvironment. Conclusion: KIF18B is a key factor affecting the prognosis of GBM patients, and its targeting may provide a new therapeutic method for GBM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.